US20120277230A1 - Compounds useful for treating cancer - Google Patents

Compounds useful for treating cancer Download PDF

Info

Publication number
US20120277230A1
US20120277230A1 US13/377,745 US201013377745A US2012277230A1 US 20120277230 A1 US20120277230 A1 US 20120277230A1 US 201013377745 A US201013377745 A US 201013377745A US 2012277230 A1 US2012277230 A1 US 2012277230A1
Authority
US
United States
Prior art keywords
amine
group
quinolin
hydrogen atom
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/377,745
Other languages
English (en)
Inventor
Pierre Roux
Florence Mahuteau
Romain Najman
Jamal Tazi
Gilles Gadea
Didier Scherrer
Carsten Brock
Nathalie Cahuzac
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SPLICOS CAMPUS DU CNRS Ste
Centre National de la Recherche Scientifique CNRS
Universite Montpellier 2 Sciences et Techniques
Institut Curie
SPLICOS STE
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite Montpellier 2 Sciences et Techniques
Institut Curie
SPLICOS STE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20090305540 external-priority patent/EP2266972A1/en
Priority claimed from EP09162630A external-priority patent/EP2261214A1/en
Application filed by Centre National de la Recherche Scientifique CNRS, Universite Montpellier 2 Sciences et Techniques, Institut Curie, SPLICOS STE filed Critical Centre National de la Recherche Scientifique CNRS
Priority to US13/377,745 priority Critical patent/US20120277230A1/en
Assigned to CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE MONTPELLIER 2, INSTITUT CURIE, SOCIETE SPLICOS CAMPUS DU CNRS reassignment CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CAHUZAC, Nathalie, GADEA, GILLES, BROCK, Carsten, ROUX, PIERRE, SCHERRER, DIDIER, TAZI, JAMAL, Mahuteau, Florence, Najman, Romain
Publication of US20120277230A1 publication Critical patent/US20120277230A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention is generally dedicated to the use of compounds for the manufacture of compositions useful to treat cancer.
  • Metastases are considered as a recurrent feature of uncontrolled malignant progression of cancer. During this process, tumor cells complete their malignant transformation by increasing their migratory capacity. Cancer cells can then disseminate and establish tumor foci in far away sites. Spreading of cancer cells in the organism is the outcome of a series of events called ⁇ metastatic cascade>>: invasion of the tissues around the tumor, venous or lymphatic intravasation, migration and establishment in a distant place of a new colony that escapes from all the defence mechanisms of the organism.
  • Metastatic invasion against which there is no efficient therapeutic option available at this time, is by far the major cause of death. Due to the frequency of cancers diagnosed at the metastatic stage and to the therapeutic impasse they represent, the development of molecules that specifically target metastatic invasion is thus a crucial requirement for a major breakthrough in cancer treatments.
  • the present invention is in keeping with the evidence as published during the last twenty years of a link between changes in RNA alternative splicing and metastatic invasion which has opened to new therapeutic strategies.
  • the present invention therefore relates to compounds of formula (I) as defined below for use as agents for preventing, inhibiting or treating cancer.
  • the present invention moreover relates to a method of preventing, inhibiting or treating cancer, which comprises at least one step consisting in administering to a patient suffering therefrom an effective amount of a compound as defined in formula (I) below or one of its pharmaceutically acceptable salts.
  • the present invention further relates to some particular derivatives as such, as defined below.
  • the present invention also provides pharmaceutical compositions comprising at least one of said particular compounds.
  • a subject-matter of the present invention relates to a compound of formula (I)
  • V means an aromatic ring wherein V is C or N and when V is N, V is in ortho, meta or para of Z, i.e. forms respectively a pyridazine, a pyrimidine or a pyrazine group,
  • R independently represent a hydrogen atom, a halogen atom or a group chosen among a —CN group, a hydroxyl group, a —COOR 1 group, a (C 1 -C 3 )fluoroalkyl group, a (C 1 -C 3 )fluoroalkoxy group, a —NO 2 group, a —NR 1 R 2 group, a (C 1 -C 4 )alkoxy group, a phenoxy group and a (C 1 -C 3 )alkyl group, said alkyl being optionally mono-substituted by a hydroxyl group,
  • R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group
  • n 1, 2 or 3
  • n′ 1 or 2
  • R′ is a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a halogen atom, a hydroxyl group, a —COOR 1 group, a —NO 2 group, a —NR 1 R 2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C 1 -C 3 )fluoroalkyl group, a (C 1 -C 4 )alkoxy group and a —CN group,
  • R′′ is a hydrogen atom or a (C 1 -C 4 )alkyl group
  • Z is N or C
  • Y is N or C
  • X is N or C
  • W is N or C
  • T N or C
  • the present invention relates to a compound of formula (I) as defined above, wherein Z is N, V is C, Y is N, X is C, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating cancer.
  • the present invention relates to a compound of formula (I) as defined above, wherein Z is C, V is C, Y is N, X is C, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating cancer.
  • the present invention relates to a compound of formula (I) as defined above, wherein Z is N, V is C, Y is C, X is N, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating cancer.
  • the present invention relates to a compound of formula (I) as defined above, wherein Z is N, V is C, Y is C, X is C, T is C, U is C and W is N, for use as an agent for preventing, inhibiting or treating cancer.
  • the present invention relates to a compound of formula (I) as defined above, wherein Z is N, V is N and is in para of Z, Y is N, X is C, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating cancer.
  • the present invention relates to a compound of formula (I) as defined above, wherein Z is C, V is N and is in para of Z, Y is C, X is N, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating cancer.
  • the present invention relates to a compound of formula (I) as defined above, wherein Z is C, V is N and is in meta of Z and is in para of the bond linked to NR′′, Y is N, X is C, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating cancer.
  • the present invention relates to a compound of formula (I) as defined above, wherein Z is C, V is N and is in meta of Z and is in para of the bond linked to NR′′, Y is C, X is N, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating cancer.
  • the present invention relates to a compound of formula (I) as defined above, wherein Z is C, V is C, Y is C, X is N, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating cancer.
  • the present invention relates to a compound of formula (I) as defined above, wherein Z is C, V is C, Y is N, X is N, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating cancer.
  • the present invention relates to a compound of formula (I) as defined above, wherein Z is N, V is N and is in meta of Z and in ortho of the bond linked to NR′′, Y is N, X is C, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating cancer.
  • the present invention relates to a compound of formula (I) as defined above, wherein Z is N, V is N and is in para of Z, Y is C, X is C, T is C, U is C and W is N, for use as an agent for preventing, inhibiting or treating cancer.
  • the present invention relates to a compound of formula (I) as defined above, wherein Z is N, V is N and is in para of Z, Y is C, X is N, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating cancer.
  • the present invention relates to a compound of formula (I) as defined above, wherein Z is N, V is C, Y is N, X is N, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating cancer.
  • the present invention relates to a compound of formula (I) as defined above, wherein Z is N, V is N and is in meta of Z and is in ortho of the bond linked to NR′′, Y is N, X is N, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating cancer.
  • the present invention relates to a compound of formula (I) as defined above, wherein Z is C, V is C, Y is C, X is C, T is N, U is C and W is C, for use as an agent for preventing, inhibiting or treating cancer.
  • the present invention relates to a compound of formula (I) as defined above, wherein Z is N, V is C, Y is C, X is C, T is N, U is C and W is C, for use as an agent for preventing, inhibiting or treating cancer.
  • the present invention relates to a compound of formula (I) as defined above, wherein Z is N, V is C, Y is C, X is C, T is C, U is N and W is C, for use as an agent for preventing, inhibiting or treating cancer.
  • the present invention relates to a compound of formula (I) as defined above, wherein Z is N, V is C, Y is N, X is C, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating cancer.
  • the present invention relates to a compound of formula (I) as defined above, wherein Z is N, V is N and is in para of Z, Y is N, X is C, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating cancer.
  • the present invention relates to a compound of formula (I) as defined above, wherein Z is C, V is C, Y is C, X is C, T is N, U is C and W is C, for use as an agent for preventing, inhibiting or treating cancer.
  • the present invention relates to a compound of formula (I) as defined above, wherein Z is N, V is C, Y is C, X is C, T is C, U is N and W is C, for use as an agent for preventing, inhibiting or treating cancer.
  • the compounds of the invention may exist in the form of free bases or of addition salts with pharmaceutically acceptable acids.
  • Suitable physiologically acceptable acid addition salts of compounds of formula (I) include hydrobromide, tartrate, citrate, trifluoroacetate, ascorbate, hydrochloride, tartrate, triflate, maleate, mesylate, formate, acetate and fumarate.
  • the compounds of formula (I) and or salts thereof may form solvates (e.g. hydrates) and the invention includes all such solvates.
  • halogen is understood to mean chlorine, fluorine, bromine, or iodine, and in particular denotes chlorine, fluorine or bromine,
  • (C 1 -C 3 )alkyl as used herein respectively refers to C 1 -C 3 normal, secondary or tertiary saturated hydrocarbon. Examples are, but are not limited to, methyl, ethyl, 1-propyl, 2-propyl,
  • (C 1 -C 3 )alkoxy as used herein respectively refers to O—(C 1 -C 3 )alkyl moiety, wherein alkyl is as defined above. Examples are, but are not limited to, methoxy, ethoxy, 1-propoxy, 2-propoxy,
  • fluoroalkyl group and fluoroalkoxy group refers respectively to alkyl group and alkoxy group as above-defined, said groups being substituted by at least one fluorine atom.
  • perfluoroalkyl groups such as trifluoromethyl or perfluoropropyl, and
  • patient may extend to humans or mammals, such as cats or dogs.
  • an additional subject-matter of the present invention is a compound of formula (Ia)
  • R independently represent a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a —CN group, a hydroxyl group, a —COOR 1 group, a (C 1 -C 3 )fluoroalkyl group, a —NO 2 group, a —NR 1 R 2 group and a (C 1 -C 3 )alkoxy group,
  • R′′ is as defined above and is advantageously a hydrogen atom
  • n is as defined above and is advantageously 1,
  • n′ is as defined above and is advantageously 1,
  • R′ is a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a —NO 2 group, a (C 1 -C 3 )alkoxy group and a —NR 1 R 2 group,
  • R 1 and R 2 are a hydrogen atom or a (C 1 -C 3 )alkyl group
  • an additional subject-matter of the present invention is a compound of formula (Ib)
  • R independently represent a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a —NR 1 R 2 group, a (C 1 -C 3 )fluoroalkoxy group, a —NO 2 group, a phenoxy group and a (C 1 -C 4 )alkoxy group,
  • R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group
  • R′′ is as defined above and is advantageously a hydrogen atom
  • n is as defined above and is preferably 1 or 2
  • n′ is as defined above and is preferably 1,
  • R′ is a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group and a (C 1 -C 4 )alkoxy group,
  • an additional subject-matter of the present invention is a compound of formula (Ic)
  • R independently represent a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a (C 1 -C 3 )fluoroalkyl group, a —NR 1 R 2 group, a —COOR 1 group, a —NO 2 group and a (C 1 -C 3 )alkoxy group,
  • R′′ is as defined above and is advantageously a hydrogen atom
  • n is as defined above and is advantageously 1,
  • n′ is as defined above and is advantageously 1,
  • R′ is a hydrogen atom
  • R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group
  • an additional subject-matter of the present invention is a compound of formula (Id)
  • R independently represent a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a (C 1 -C 3 )fluoroalkyl group and a (C 1 -C 3 )alkoxy group,
  • R′′ is as defined above and is advantageously a hydrogen atom
  • n is as defined above and is advantageously 1,
  • n′ is as defined above and is advantageously 1,
  • R′ is a hydrogen atom
  • an additional subject-matter of the present invention is a compound of formula (Ie)
  • R represents a hydrogen atom
  • R′′ is as defined above and is advantageously a hydrogen atom
  • n is as defined above and is advantageously 1,
  • n′ is as defined above and is advantageously 1,
  • R′ is a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group and a (C 1 -C 3 )alkoxy group,
  • an additional subject-matter of the present invention is a compound of formula (If)
  • R represents a hydrogen atom
  • R′′ is as defined above and is advantageously a hydrogen atom
  • n is as defined above and is advantageously 1,
  • n′ is as defined above and is advantageously 1,
  • R′ is a hydrogen atom
  • an additional subject-matter of the present invention is a compound of formula (Ig)
  • R represents a hydrogen atom
  • R′′ is as defined above and is advantageously a hydrogen atom
  • n is as defined above and is advantageously 1,
  • n′ is as defined above and is advantageously 1,
  • R′ is a hydrogen atom or a halogen atom
  • an additional subject-matter of the present invention is a compound of formula (Ii)
  • R represents a hydrogen atom
  • R′′ is as defined above and is advantageously a hydrogen atom
  • n is as defined above and is advantageously 1,
  • n′ is as defined above and is advantageously 1,
  • R′ is a hydrogen atom
  • an additional subject-matter of the present invention is a compound of formula (Ii)
  • R independently represent a hydrogen atom or a group chosen among a (C 1 -C 3 )fluoroalkoxy group and a (C 1 -C 3 )alkoxy group,
  • R′′ is as defined above and is advantageously a hydrogen atom
  • n is as defined above and is advantageously 1,
  • n′ is as defined above and is advantageously 1,
  • R′ is a hydrogen atom
  • an additional subject-matter of the present invention is a compound of formula (Ij)
  • R independently represent a hydrogen atom or a group chosen among a (C 1 -C 3 )fluoroalkoxy group and a (C 1 -C 3 )alkyl group,
  • R′′ is as defined above and is advantageously a hydrogen atom
  • n is as defined above and is advantageously 1,
  • n′ is as defined above and is advantageously 1,
  • R′ is a hydrogen atom
  • an additional subject-matter of the present invention is a compound of formula (Ik)
  • R represents a hydrogen atom
  • R′′ is as defined above and is advantageously a hydrogen atom
  • n is as defined above and is advantageously 1,
  • n′ is as defined above and is advantageously 1,
  • R′ is a hydrogen atom, a halogen atom or a (C 1 -C 3 )alkyl group
  • an additional subject-matter of the present invention is a compound of formula (Il)
  • R represents a hydrogen atom
  • R′′ is as defined above and is advantageously a hydrogen atom
  • n is as defined above and is advantageously 1,
  • n′ is as defined above and is advantageously 1,
  • R′ is a hydrogen atom
  • an additional subject-matter of the present invention is a compound of formula (Im)
  • R represents a hydrogen atom
  • R′′ is as defined above and is advantageously a hydrogen atom
  • n is as defined above and is advantageously 1,
  • n′ is as defined above and is advantageously 1,
  • R′ is a hydrogen atom
  • an additional subject-matter of the present invention is a compound of formula (Io)
  • R independently represent a hydrogen atom or a halogen atom or a group chosen among, a —NO 2 group, a —CN group and a (C 1 -C 3 )alkyl group, said alkyl being optionally mono-substituted by a hydroxyl group,
  • R′′ is as defined above and is advantageously a hydrogen atom
  • n is as defined above and is advantageously 1,
  • n′ is as defined above and is advantageously 1,
  • R′ is a hydrogen atom, a halogen atom or a (C 1 -C 3 )fluoroalkyl group
  • an additional subject-matter of the present invention is a compound of formula (Ip)
  • R represents a hydrogen atom
  • R′′ is as defined above and is advantageously a hydrogen atom
  • n is as defined above and is advantageously 1,
  • n′ is as defined above and is advantageously 1,
  • R′ is a hydrogen atom
  • an additional subject-matter of the present invention is a compound of formula (Iq)
  • R independently represent a hydrogen atom, a (C 1 -C 3 )alkoxy group or a (C 1 -C 3 )fluoroalkoxy group
  • R′′ is as defined above and is advantageously a hydrogen atom
  • n is as defined above and is advantageously 1,
  • n′ is as defined above and is advantageously 1,
  • R′ is a hydrogen atom or a group chosen among a —NR 1 R 2 group, a N-methylpiperazinyl group, a (C 1 -C 3 )alkoxy group and a morpholino group,
  • R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group
  • an additional subject-matter of the present invention is a compound of formula (Ir)
  • R independently represent a hydrogen atom or a (C 1 -C 3 )alkyl group
  • R′′ is as defined above and is advantageously a hydrogen atom
  • n is as defined above and is advantageously 1,
  • n′ is as defined above and is advantageously 1,
  • R′ is a hydrogen atom or a group chosen among a —NR 1 R 2 group, a morpholino group and a (C 1 -C 3 )alkoxy group,
  • R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group
  • an additional subject-matter of the present invention is a compound of formula (Iee)
  • R independently represent a hydrogen atom, a (C 1 -C 3 )alkyl group or a (C 1 -C 3 )fluoroalkyl group,
  • R′′ is as defined above and is advantageously a hydrogen atom
  • n is as defined above and is advantageously 1,
  • n′ is as defined above and is advantageously 2,
  • R′ is a hydrogen atom or a (C 1 -C 3 )alkyl group
  • the present invention further relates to a compound chosen among compounds of formulae (Ia), (Ie), (Iq) and (Iee), and their pharmaceutically acceptable salts for use as an agent for preventing, inhibiting or treating cancer.
  • the present invention more particularly focuses on a compound of formula (Ia)
  • R independently represent a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a —CN group, a —COOR 1 group and a (C 1 -C 3 )fluoroalkyl group,
  • R′′ is as defined above and more preferably is a hydrogen atom
  • R 1 is as defined above,
  • n is as defined above
  • n′ is as defined above
  • R′ is a halogen atom, a (C 1 -C 4 )alkyl group, a (C 1 -C 4 )alkoxy group or a —NO 2 group,
  • the present invention more particularly focuses on a compound of formula (Ie)
  • R represents a hydrogen atom or a (C 1 -C 4 )alkyl group
  • R′′ is as defined above and more preferably is a hydrogen atom
  • n is as defined above
  • n′ is as defined above
  • R′ is a halogen atom
  • the present invention more particularly focuses on a compound of formula (Iq)
  • R′, R′′, n and n′ are as defined in formula (I), and
  • R is a (C 1 -C 3 )fluoroalkoxy group
  • the present invention more particularly focuses on a compound of formula (Iee)
  • R is independently a hydrogen atom or a (C 1 -C 4 )alkyl group
  • R′, R′′, n and n′ are as defined in formula (I),
  • the present invention relates to a compound of formula (Ia) or (Ie) as defined above or one of its pharmaceutically acceptable salts, for use as an agent for preventing, inhibiting or treating cancer.
  • the compound for use as an agent for preventing, inhibiting or treating cancer is chosen from:
  • the present invention therefore extends to compounds (6), (18), (30), (35), (36), (37), (45), (48), (51), (52), (53), (55), (56), (58), (61), (63), (64), (109), (110), (112), (143), (144) and (148) or one of its pharmaceutically acceptable salts for use as an agent for preventing, inhibiting or treating cancer.
  • the compounds of formulae (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Il), (Im), (Io), (Ip), (Iq), (Ir) and (Iee) can comprise one or more asymmetric carbon atoms. They can thus exist in the form of enantiomers or of diastereoisomers. These enantiomers, diastereoisomers and their mixtures, including the racemic mixtures, are encompassed within the scope of the present invention.
  • the present invention encompasses compounds of formula (Ig)
  • R independently represent a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a —CN group, a hydroxyl group, a —COOR 1 group, a (C 1 -C 3 )fluoroalkyl group, a (C 1 -C 3 )fluoroalkoxy group, a —NO 2 group, a —NR 1 R 2 group, and a (C 1 -C 3 )alkoxy group,
  • n 1 or 2
  • n′ 1 or 2
  • R′ is a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a halogen atom, a hydroxyl group, a —COOR 1 group, a —NO 2 group, a —NR 1 R 2 group, a (C 1 -C 3 )alkoxy group and a —CN group,
  • R′′ is a hydrogen atom or a (C 1 -C 4 )alkyl group
  • R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group
  • the present invention encompasses compounds of formula (If)
  • R independently represent a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a —CN group, a hydroxyl group, a —COOR 1 group, a (C 1 -C 3 )fluoroalkyl group, a (C 1 -C 3 )fluoroalkoxy group, a —NO 2 group, a —NR 1 R 2 group, and a (C 1 -C3)alkoxy group,
  • n 1 or 2
  • n′ 1 or 2
  • R′ is a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a halogen atom, a hydroxyl group, a —COOR 1 group, a —NO 2 group, a —NR 1 R 2 group, a (C 1 -C 3 )alkoxy group and a —CN group,
  • R′′ is a hydrogen atom or a (C 1 -C 4 )alkyl group
  • R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group
  • the present invention encompasses compounds of formula (Ih)
  • R independently represent a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a —CN group, a hydroxyl group, a —COOR 1 group, a (C 1 -C 3 )fluoroalkyl group, a (C 1 -C 3 )fluoroalkoxy group, a —NO 2 group, a —NR 1 R 2 group, and a (C 1 -C 3 )alkoxy group,
  • n 1 or 2
  • n′ 1 or 2
  • R′ is a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a halogen atom, a hydroxyl group, a —COOR 1 group, a —NO 2 group, a —NR 1 R 2 group, a (C 1 -C 3 )alkoxy group and a —CN group,
  • R′′ is a hydrogen atom or a (C 1 -C 4 )alkyl group
  • R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group
  • the present invention encompasses compounds of formula (II)
  • R independently represent a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a —CN group, a hydroxyl group, a —COOR 1 group, a (C 1 -C 3 )fluoroalkyl group, a (C 1 -C 3 )fluoroalkoxy group, a —NO 2 group, a —NR 1 R 2 group, and a (C 1 -C 3 )alkoxy group,
  • n 1 or 2
  • n′ 1 or 2
  • R′ is a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a halogen atom, a hydroxyl group, a —COOR 1 group, a —NO 2 group, a —NR 1 R 2 group, a (C 1 -C 3 )alkoxy group and a —CN group,
  • R′′ is a hydrogen atom or a (C 1 -C 4 )alkyl group
  • R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group
  • the present invention encompasses compounds of formula (Im)
  • R independently represent a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a —CN group, a hydroxyl group, a —COOR 1 group, a (C 1 -C 3 )fluoroalkyl group, a (C 1 -C 3 )fluoroalkoxy group, a —NO 2 group, a —NR 1 R 2 group, and a (C 1 -C 3 )alkoxy group,
  • n 1 or 2
  • n′ 1 or 2
  • R′ is a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a halogen atom, a hydroxyl group, a —COOR 1 group, a —NO 2 group, a —NR 1 R 2 group, a (C 1 -C 3 )alkoxy group and a —CN group,
  • R′′ is a hydrogen atom or a (C 1 -C 4 )alkyl group
  • R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group
  • the present invention encompasses compounds of formula (Ia), as such,
  • R′′ and n are as defined in formula (Ia),
  • n′ 1,
  • R independently represent a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a —CN group, a hydroxyl group, a —COOR 1 group, a (C 1 -C 3 )fluoroalkyl group, a —NO 2 group, a (C 1 -C 3 )fluoroalkoxy group and a (C 1 -C 3 )alkoxy group,
  • R′ is a hydrogen atom or a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a —COOR 1 group, and a —CN group,
  • R 1 is a hydrogen atom or a (C 1 -C 3 )alkyl group:
  • R is not a methyl group in ortho or para position with respect to Z, Z being N,
  • R′ is a hydrogen atom, R is not a bromine atom or a chlorine atom,
  • R when R is a hydrogen atom, R′ is not a methyl or ethyl group, a —COOH group, a COOC 2 H 5 group or a bromine atom, said bromine atom being in ortho position of the bond linked to NR′′,
  • R independently represent a hydrogen atom or a (C 1 -C 3 )alkyl group
  • R′′ is as defined in formula (Ia),
  • R′ is a hydrogen atom, a halogen atom, a (C 1 -C 3 )alkoxy group or a —NO 2 group,
  • n′ 1,
  • n 1,
  • R is not a methyl group in ortho or para position with respect to Z, Z being N,
  • the present invention more preferably focuses on compounds of formula (Ia′), as such,
  • R independently represent a hydrogen atom, a (C 1 -C 3 )alkyl group, a (C 1 -C 3 )fluoroalkyl group, a halogen atom or a hydroxyl group,
  • R′′ is as defined in formula (Ia),
  • n 1 or 2
  • the present invention encompasses compounds of formula (Ie)
  • R, R′, R′′ n and n′ are as defined in formula (I),
  • R′ is not a bromine atom
  • the present invention further relates to a compound of formula (Iq) as defined above, as such
  • R, R′, R′′ and n′ are as defined in formula (I),
  • n 1 or 2
  • R′ and R are not simultaneously a hydrogen atom
  • R′ is a hydrogen atom, R is not a —NO 2 group or a —NH 2 group,
  • R′ is a hydrogen atom
  • R is not a COOC 2 H 5 group or a chlorine atom
  • R′, R′′, n and n′ are as defined in formula (I), and
  • R is a (C 1 -C 3 )fluoroalkoxy group
  • R, R′′, n and n′ are as defined in formula (I), and
  • R′ is a —NR 1 R 2 group
  • R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group
  • R, R′′, n and n′ are as defined in formula (I), and
  • R′ is a morpholinyl group, a morpholino group or a N-methylpiperazinyl group
  • the present invention further relates to a compound of formula (Iee) as defined above, as such
  • R, R′, R′′, n and n′ are as defined in formula (I),
  • R is a —NO 2 group or a —NH 2 group when R′ is a hydrogen or a methyl group.
  • R′, R′′, n and n′ are as defined in formula (I), and
  • R is a (C 1 -C 3 )fluoroalkyl group
  • compounds (1), (2), (5)-(8), (10)-(16), (18), (21)-(44), (46)-(75), (77)-(84), (86)-(119), (121), (124)-(130), (132), (135)-(141), (143)-(147), (149)-(168) and their pharmaceutically acceptable salts are of particular interest.
  • the present invention therefore extends to compounds (1), (2), (5)-(8), (10)-(16), (18), (21)-(44), (46)-(75), (77)-(84), (86)-(119), (121), (124)-(130), (132), (135)-(141), (143)-(147), (149)-(168) and their pharmaceutically acceptable salts, as such.
  • the present invention therefore extends to compounds (143), (144), (149), (166), (167) and their pharmaceutically acceptable salts, such as hydrobromide, tartrate, citrate, trifluoroacetate, ascorbate, hydrochloride, tartrate, triflate, maleate, mesylate, formate, acetate and fumarate.
  • pharmaceutically acceptable salts such as hydrobromide, tartrate, citrate, trifluoroacetate, ascorbate, hydrochloride, tartrate, triflate, maleate, mesylate, formate, acetate and fumarate.
  • the present invention extends to compounds (143), (144) and their pharmaceutically acceptable salts, such as hydrobromide, tartrate, citrate, trifluoroacetate, ascorbate, hydrochloride, tartrate, triflate, maleate, mesylate, formate, acetate and fumarate.
  • pharmaceutically acceptable salts such as hydrobromide, tartrate, citrate, trifluoroacetate, ascorbate, hydrochloride, tartrate, triflate, maleate, mesylate, formate, acetate and fumarate.
  • the new compounds of the present invention i.e. compounds of formulae (Ia), (Ie), (Iq) and (Iee) and the specific compounds as listed above, are not only useful as agent for inhibiting, preventing or treating cancer but can also be useful for inhibiting, preventing or treating premature aging or progeria and for inhibiting, preventing or treating AIDS.
  • said compounds may be useful to inhibit, prevent and/or treat diseases with premature aging and that are likely related to an aberrant splicing of the nuclear lamin A gene.
  • said disease may include Hutchinson Guilford Progeria Syndrome (HGPS), progeria, premature aging associated with HIV infection, muscular dystrophy, Charcot-Marie-Tooth disorder, Werner syndrome, but also atherosclerosis, insulin resistant type II diabetes, cataracts, osteoporosis and aging of the skin such as restrictive dermopathy.
  • HGPS Hutchinson Guilford Progeria Syndrome
  • the compounds of the present invention can be prepared by conventional methods of organic synthesis practiced by those skilled in the art.
  • the general reaction sequences outlined below represent a general method useful for preparing the compounds of the present invention and are not meant to be limiting in scope or utility.
  • the synthesis is based on a coupling reaction alternatively starting from a halogeno-bicycle of formula (III), wherein X, Y, W, T, U, n′, R′ and R′′ are as defined above and X′ is a chlorine atom or a bromine atom or from a chloro-monocycle of formula (V), wherein Z, V, n and R are as defined above and X′ is a chlorine atom or a bromine atom.
  • a halogeno-bicycle of formula (III) wherein X, Y, W, T, U, n′, R′ and R′′ are as defined above and X′ is a chlorine atom or a bromine atom or from a chloro-monocycle of formula (V), wherein Z, V, n and R are as defined above and X′ is a chlorine atom or a bromine atom.
  • the compound of formula (III) is placed in a protic solvent such as tert-butanol.
  • the compound of formula (IV) is then added in a molar ratio ranging from 1 to 1.5 with respect to the compound of formula (III) in presence of an inorganic base, such as Cs 2 CO 3 or K 2 CO 3 in a molar ratio ranging from 1 and 2, in the presence of a diphosphine, such as Xantphos (4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene) or X-Phos (2-Dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl) in an amount ranging from 2 mol % to 10 mol % relative to the total amount of compound of formula (III), and in the presence of a catalyst, such as Pd(OAc) 2 or Pd 2 dba 3 in an amount ranging from 2 mol % to 10
  • the reaction mixture can then be heated at a temperature ranging from 80 to 120° C., for example at 90° C. and stirred for a time ranging form 15 to 25 hours, for example during 20 hours under inert gas and for example argon.
  • the reaction mixture can be concentrated under reduced pressure.
  • the compound of formula (V) is placed in a protic solvent such as tert-butanol.
  • the compound of formula (VI) is then added in a molar ratio ranging from 1 to 1.5 with respect to the compound of formula (V) in presence of an inorganic base, such as Cs 2 CO 3 or K 2 CO 3 in a molar ratio ranging from 1 to 2, in the presence of a diphosphine, such as Xantphos (4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene) or X-Phos (2-Dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl) in an amount ranging from 2 mol % to 10 mol % relative to the total amount of compound of formula (V), and in the presence of a catalyst, such as Pd(OAc) 2 or Pd 2 dba 3 in an amount ranging from 2 mol % to 10
  • the reaction mixture can then be heated at a temperature ranging from 80 to 120° C., for example at 90° C. and stirred for a time ranging form 15 to 25 hours, for example during 20 hours under inert gas and for example argon.
  • the reaction mixture can be concentrated under reduced pressure.
  • the compound of formula (III) is placed in a protic solvent such as tert-butanol.
  • the compound of formula (IV) is then added in a 1.1 molar ratio with respect to the compound of formula (III) in presence of an inorganic base, such as Cs 2 CO 3 or K 2 CO 3 , in a 2.8 molar ratio, in the presence of a diphosphine, such as Xantphos (4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene), or X-Phos 2-Dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl in a 2 mol % amount relative to the total amount of compound of formula (III), and in the presence of a catalyst, such as Pd(OAc) 2 or Pd 2 dba 3 in a 2 mol % amount relative to the total amount of compound of formula (III).
  • a catalyst such as Pd(OA
  • reaction mixture is then heated at 90° C., and stirred during 20 hours, under argon.
  • the reaction mixture is concentrated under reduced pressure and the resulting residue is diluted with ethyl acetate.
  • the organic phase is then washed twice with water, dried on magnesium sulphate, filtered and concentrated under reduced pressure.
  • the residue could then be purified by column chromatography on silica gel to yield pure compounds (51), (64), (110), and (143).
  • the compound of formula (V) is placed in a protic solvent such as tert-butanol.
  • the compound of formula (VI) is then added in a 1.1 molar ratio with respect to the compound of formula (V) in presence of Cs 2 CO 3 in a 2.8 molar ratio, in the presence of Xantphos (4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene) in a 2 mol % amount relative to the total amount of compound of formula (V), and in the presence of a Pd(OAc) 2 , in a 2 mol % amount relative to the total amount of compound of formula (V).
  • Xantphos 4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene
  • reaction mixture is then heated at 90° C., and stirred during 20 hours, under argon.
  • the reaction mixture is concentrated under reduced pressure and the resulting residue is diluted with ethyl acetate.
  • the organic phase is then washed twice with water, dried on magnesium sulphate, filtered and concentrated under reduced pressure.
  • the residue could then be purified by column chromatography on silica gel to yield pure compound (148).
  • a key step in the generation of tumor metastasis is the invasion of tumor cells into the extracellular matrix, a major component of which is collagen. Therefore, the invasion of tumor cells into collagen in vitro may be indicative of the generation of metastasis in vivo.
  • MDA-MB231-luc-D3H2LN mouse breast cancer cells display indeed both higher invasion into collagen in vitro and a higher metastatic potential in vivo as compared to MDA-MB231 cells (from which they were derived).
  • the aim of the experiment described here is to identify drug compounds that inhibit the invasion of tumor cells into collagen in vitro, therefore potentially inhibiting also the generation of tumor metastasis in vivo.
  • Step 1 Preparation of cells at the bottom of a collagen gel: Cells are suspended in a liquid collagen solution (4° C.), distributed into BSA-coated wells, and then collected at the bottom of the wells by centrifugation. The collagen is then solidified by incubation at 37° C. The BSA coating improves the adhesion of the collagen gel.
  • Step 2 Pre-treatment with the compounds to be tested: Concentrated drug solutions are then added on top of the collagen, and cells are pre-incubated for 24 h with the drugs at low serum conditions (0.025% FBS).
  • Step 3 Stimulation of invasion: Medium with 5% FBS is then added in order to stimulate invasion of the cells into the collagen gel.
  • Step 4 Fixation and staining: Following another 24 h incubation, cells are fixed and nuclei are stained.
  • Step 5 Analysis: Finally, plates are analyzed using an automated microscope. Fluorescent beads that have been included into the BSA coating serve to detect the bottom of the wells. Pictures of the stained nuclei are taken at the same level (0 ⁇ m) as well as 25 ⁇ m and 50 ⁇ m above.
  • the viability assay is performed in parallel on serum-starved cells (as in the invasion assay) vs. cells under normal culture conditions (10% FBS).
  • rat tail collagen type 1: BD Biosciences, ref. 354236 (note: each new lot has to be validated)
  • red fluorescent beads (1 ⁇ m diameter): Invitrogen, ref. F13083
  • Y-27632 (5 mM aqueous solution): Calbiochem, ref. 688001 (in solution) or 688000 (dry powder)
  • MTS reagent Promega CellTiter CellTiter 96® AQueous One Solution Reagent, ref. G3581
  • drug compounds to be tested generally 25 or 50 mM in 100% DMSO (aliquots stored at ⁇ 20° C., then at 4° C. for max. 3 months)
  • cell density between 50 and 90% (optimally 70%) (between 1 and 2 ⁇ 106 cells per 100 mm dish)
  • Viability assays No additional controls.
  • the MTS viability assay is based on colorimetric detection of a product generated by the mitochondrial activity of the cells. Each drug is tested at least in duplicate. To detect potential direct interactions with the assay substrate, each drug is also tested in absence of cells (background signals).
  • Typical plate map controls and drug compounds as in the invasion assay, lines A-B and E-F: with cells, lines C-D and G-H: without cells; each 1 plate with 10% vs. 0.025% FBS):
  • the volumes or other quantities indicated in the following are required for testing 16 drug compounds per 96 wells-plate at 5 ⁇ M each (+controls) in an invasion assay and each one viability assay on serum-starved cells vs. cells under normal culture conditions according to the plate maps above. According to the number of tested compounds, the volumes and other quantities should be adapted for testing more or less compounds or different concentrations.
  • negative controls add each 20 ⁇ l 110% DMSO in sterile PBS
  • centrifuge 30′ with 1800 ⁇ g at 4° C. (e.g. 3000 rpm in a Jouan GR412 centrifuge)
  • centrifuge 5′ with 200 ⁇ g at 4° C. e.g. 1000 rpm in a Jouan GR412 centrifuge
  • MTS assay MTS assay
  • channel 1 (autofocus on, and photo of the fluorescent beads at the bottom of the wells): filter: XF93-TRITC; exposure time: usually between 0.002 and 0.01 s
  • channel 2 photo of the stained cells at the same level as the fluorescent beads: filter: XF100-Hoechst; exposure time: usually between 0.02 and 0.1 s; z offset: 0 ⁇ M
  • channel 3 photo of the stained cells 25 ⁇ M above the fluorescent beads: filter: XF100-Hoechst; exposure time: usually between 0.02 and 0.1 s; z offset: ⁇ 25 ⁇ M
  • channel 4 photo of the fluorescent cells 50 ⁇ M above the fluorescent beads: filter: XF100-Hoechst; exposure time: usually between 0.02 and 0.1 s; z offset: ⁇ 50 ⁇ M
  • object identification method: fixed threshold: 100-32767
  • Y27632 is a selective inhibitor of the Rho-associated protein kinase p160ROCK of the following formula
  • plot graphs of all four parameters (number of cells at 0 ⁇ m, number of cells at 25 ⁇ m, number of cells at 50 ⁇ m, mean invasion distance of the counted cells)
  • the compounds according to the present invention demonstrate an anti-invasive effect predictive for their activity against cancer.
  • the result of the tests carried out on the compounds disclosed in the present invention show that said compounds may be useful to inhibit, prevent and/or treat cancer.
  • the following type of cancer may more particularly be treated by the compounds according to the present invention: colorectal cancer, pancreatic cancer, lung cancer including non-small cell lung cancer, breast cancer, bladder cancer, gall bladder cancer, thyroid cancer, melanoma, liver cancer, uterine/cervical cancer, oesophageal cancer, kidney cancer, ovarian cancer, prostate cancer, head and neck cancer, and stomach cancer, etc.
  • an effective amount of a said compound may be administered to a patient suffering from cancer.
  • the present invention is also related to the use of at least a compound chosen among a compound of anyone of formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Il), (Im), (Io), (Ip), (Iq), (Ir) or (Iee) as defined above, and compounds (I) to (168) as defined above, or one of its pharmaceutically acceptable salts according to the present invention for the manufacture of a pharmaceutical composition intended for the treatment of cancer.
  • the present invention also encompasses pharmaceutical compositions comprising at least a compound chosen among new compounds of formula (Iq) or (Iee) as defined above and compounds (143), (144), (149), (166) and (167) as defined above or any pharmaceutically acceptable salt thereof.
  • compositions contain an effective amount of said compound, and one or more pharmaceutical excipients.
  • excipients are selected according to the dosage form and the desired mode of administration.
  • any pharmaceutical form which is suitable for enteral or parenteral administration, in association with appropriate excipients, for example in the form of plain or coated tablets, hard gelatine, soft shell capsules and other capsules, suppositories, or drinkable, such as suspensions, syrups, or injectable solutions or suspensions, in doses which enable the daily administration of from 0.1 to 1000 mg of active substance.
  • the present invention is also related to the use of a compound of anyone of formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Il), (Im), (Io), (Ip), (Iq), (Ir) or (Iee) as defined above, and compounds (I) to (168) as defined above, or one of its pharmaceutically acceptable salts according to the present invention for the manufacture of a pharmaceutical composition intended for inhibiting, preventing and/or treating cancer.
  • the present invention further relates to a method of treatment of patients suffering form cancer, which comprises at least a step of administration to a patient suffering thereof of an effective amount of a compound of anyone of formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Il), (Im), (Io), (Ip), (Iq), (Ir) or (Iee) as defined above and (1) to (168) or one of its pharmaceutically acceptable salts.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
US13/377,745 2009-06-12 2010-06-14 Compounds useful for treating cancer Abandoned US20120277230A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/377,745 US20120277230A1 (en) 2009-06-12 2010-06-14 Compounds useful for treating cancer

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US18654409P 2009-06-12 2009-06-12
US18655209P 2009-06-12 2009-06-12
EP20090305540 EP2266972A1 (en) 2009-06-12 2009-06-12 New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies
EP09162630.9 2009-06-12
EP09305540.8 2009-06-12
EP09162630A EP2261214A1 (en) 2009-06-12 2009-06-12 Compounds useful to treat premature aging and in particular progeria
US13/377,745 US20120277230A1 (en) 2009-06-12 2010-06-14 Compounds useful for treating cancer
PCT/IB2010/052650 WO2010143168A2 (en) 2009-06-12 2010-06-14 Compounds useful for treating cancer

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB2010/052650 A-371-Of-International WO2010143168A2 (en) 2009-06-12 2010-06-14 Compounds useful for treating cancer
US14/789,250 Continuation-In-Part US10017498B2 (en) 2009-06-12 2015-07-01 Compounds useful for treating AIDS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/087,762 Continuation US9108919B2 (en) 2009-06-12 2013-11-22 Compounds useful for treating cancer

Publications (1)

Publication Number Publication Date
US20120277230A1 true US20120277230A1 (en) 2012-11-01

Family

ID=43309298

Family Applications (7)

Application Number Title Priority Date Filing Date
US13/377,745 Abandoned US20120277230A1 (en) 2009-06-12 2010-06-14 Compounds useful for treating cancer
US13/377,760 Active 2030-07-24 US9145367B2 (en) 2009-06-12 2010-06-14 Compounds useful for treating AIDS
US13/377,753 Abandoned US20120329796A1 (en) 2009-06-12 2010-06-14 Compounds useful for treating premature aging and in particular progeria
US14/087,762 Active US9108919B2 (en) 2009-06-12 2013-11-22 Compounds useful for treating cancer
US14/256,334 Active US9908869B2 (en) 2009-06-12 2014-04-18 Compounds useful for treating aids
US14/789,250 Active US10017498B2 (en) 2009-06-12 2015-07-01 Compounds useful for treating AIDS
US14/789,149 Active US9637475B2 (en) 2009-06-12 2015-07-01 Compounds for treating cancer

Family Applications After (6)

Application Number Title Priority Date Filing Date
US13/377,760 Active 2030-07-24 US9145367B2 (en) 2009-06-12 2010-06-14 Compounds useful for treating AIDS
US13/377,753 Abandoned US20120329796A1 (en) 2009-06-12 2010-06-14 Compounds useful for treating premature aging and in particular progeria
US14/087,762 Active US9108919B2 (en) 2009-06-12 2013-11-22 Compounds useful for treating cancer
US14/256,334 Active US9908869B2 (en) 2009-06-12 2014-04-18 Compounds useful for treating aids
US14/789,250 Active US10017498B2 (en) 2009-06-12 2015-07-01 Compounds useful for treating AIDS
US14/789,149 Active US9637475B2 (en) 2009-06-12 2015-07-01 Compounds for treating cancer

Country Status (24)

Country Link
US (7) US20120277230A1 (ja)
EP (6) EP3517534B1 (ja)
JP (8) JP5826745B2 (ja)
KR (14) KR101982463B1 (ja)
CN (13) CN106928194B (ja)
AU (3) AU2010258294B2 (ja)
BR (5) BR122019013686B1 (ja)
CA (5) CA3070823C (ja)
CU (4) CU24093B1 (ja)
DK (3) DK2440545T3 (ja)
ES (3) ES2938532T3 (ja)
FI (3) FI2440547T3 (ja)
HK (8) HK1173153A1 (ja)
HR (2) HRP20230248T1 (ja)
HU (2) HUE045548T2 (ja)
LT (1) LT2440547T (ja)
MX (9) MX367601B (ja)
PL (3) PL2440547T3 (ja)
PT (3) PT2440546T (ja)
RU (1) RU2567752C2 (ja)
SI (1) SI2440547T1 (ja)
TR (1) TR201910781T4 (ja)
WO (3) WO2010143168A2 (ja)
ZA (2) ZA201109032B (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10464903B2 (en) * 2016-03-18 2019-11-05 Ratiopharm Gmbh Process for preparing quinolin-2-yl-phenylamine derivatives and their salts
US11441181B2 (en) 2013-01-17 2022-09-13 Abivax miRNA-124 as a biomarker
US11649211B2 (en) 2014-07-17 2023-05-16 Abivax Use of quinoline derivatives for the treatment of inflammatory diseases
US11992499B2 (en) 2018-12-20 2024-05-28 Abivax Quinoline derivatives for use in the treatment of inflammation diseases

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106928194B (zh) 2009-06-12 2019-11-12 Abivax公司 用于治疗过早衰老和尤其是早衰的化合物
MX2019008390A (es) * 2009-06-12 2019-09-09 Abivax Compuestos utiles para tratar cancer.
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
JP5696856B2 (ja) 2009-09-03 2015-04-08 バイオエナジェニックス Ｐａｓｋの阻害用複素環式化合物
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
EP2465502A1 (en) * 2010-12-15 2012-06-20 Société Splicos Compounds useful for treating AIDS
JP5980812B2 (ja) 2011-01-05 2016-08-31 バイオエナジェニックス Ｐａｓｋの阻害のための複素環化合物
CN103459382B (zh) 2011-03-02 2016-06-29 拜奥埃内杰尼克斯公司 用于抑制pask的杂环化合物
US8916561B2 (en) 2011-03-02 2014-12-23 Bioenergenix, Llc Substituted quinoxaline compounds for the inhibition of PASK
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) * 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
FR2987627B1 (fr) * 2012-03-05 2016-03-18 Splicos Utilisation de rbm39 comme biomarqueur
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
EP2863920B1 (en) * 2012-06-20 2023-03-22 Eutropics Pharmaceuticals, Inc. Quinoline derivatives for use in the tratment of breast cancer
US9145411B2 (en) 2012-08-02 2015-09-29 Asana Biosciences, Llc Substituted amino-pyrimidine derivatives
US9487526B2 (en) 2012-08-13 2016-11-08 Takeda Pharmaceutical Company Limited Quinoxaline derivatives as GPR6 modulators
WO2014065209A1 (ja) * 2012-10-23 2014-05-01 日本曹達株式会社 ピリジン化合物またはその塩、有害生物防除剤、殺虫剤または殺ダニ剤、および外部寄生虫防除剤
US20160038503A1 (en) 2012-11-21 2016-02-11 David Richard Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
GB201301571D0 (en) * 2012-11-27 2013-03-13 Fundanci N Pedro Barri De La Maza Product and use
US20140194465A1 (en) * 2013-01-04 2014-07-10 Novarx Corporation Compositions for treatment of cancer
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
RU2681943C9 (ru) * 2013-07-05 2019-05-16 Абивакс Соединения, полезные для лечения заболеваний, вызванных ретровирусами
EP3020829B1 (en) * 2013-07-12 2021-11-17 Kyoto University Pharmaceutical composition capable of inhibiting abnormal splicing causative of onset or progress of a genetic disease
WO2015017788A1 (en) 2013-08-01 2015-02-05 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
JP6538044B2 (ja) 2013-10-30 2019-07-03 ユートロピクス ファーマシューティカルズ， インコーポレイテッド 化学療法感受性および化学毒性を判定する方法
JO3466B1 (ar) 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
JP6526034B2 (ja) 2014-02-14 2019-06-05 武田薬品工業株式会社 Ｇｐｒ６のピリドピラジンモジュレーター
WO2015144808A1 (en) 2014-03-26 2015-10-01 Astex Therapeutics Ltd Combinations of an fgfr inhibitor and an igf1r inhibitor
SI3122358T1 (sl) 2014-03-26 2021-04-30 Astex Therapeutics Ltd. Kombinacije FGFR- in CMET-inhibitorjev za zdravljenje raka
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
EP2975034A1 (en) 2014-07-17 2016-01-20 Abivax A quinoline derivative for the treatment of inflammatory diseases and AIDS
CA2973942C (en) 2015-01-30 2023-07-11 Centre National De La Recherche Scientifique (Cnrs) Delta133p53beta and delta133p53gamma isoforms are biomarkers of cancer stem cells
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
EP3059236A1 (en) 2015-02-23 2016-08-24 Abivax A new quinoline derivative for use in the treatment and prevention of viral infections
EP3058940A1 (en) * 2015-02-23 2016-08-24 Abivax Quinoline derivatives for use in the treatment or prevention of viral infection
EP3059591A1 (en) 2015-02-23 2016-08-24 Abivax Methods for screening compounds for treating or preventing a viral infection or a virus-related condition
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
ES2904513T3 (es) 2015-09-23 2022-04-05 Janssen Pharmaceutica Nv 1,4-Benzodiazepinas biheteroarilo sustituidas y usos de las mismas para el tratamiento del cáncer
BR112018005637B1 (pt) 2015-09-23 2023-11-28 Janssen Pharmaceutica Nv Compostos derivados de quinoxalina, quinolina e quinazolinona,composições farmacêuticas que os compreende, e uso dos referidos compostos
EP3390378B1 (en) 2015-12-17 2022-03-30 AlonBio Ltd. Small molecules against cancer
DK3390364T3 (da) 2015-12-17 2020-10-12 Biokine Therapeutics Ltd Små molekyler til hæmning af kemokinaktivitet og/eller cancercellevækst
EP3411083A1 (en) * 2016-02-03 2018-12-12 Janssen Pharmaceutica NV Tau pet imaging ligands
EP3484528B1 (en) * 2016-07-18 2020-11-25 Janssen Pharmaceutica NV Tau pet imaging ligands
CN106496061B (zh) * 2016-10-20 2018-06-05 湘潭大学 一种萃取分离酰化反应液中乙酰精胺的方法
AR112027A1 (es) * 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
EP3645029B1 (en) * 2017-06-26 2023-01-18 Institut Pasteur Treatments to eliminate hiv reservoirs and reduce viral load
US10889566B2 (en) * 2017-08-29 2021-01-12 Chulabhorn Foundation Derivatives and composition of quinoline and naphthyridine
US20200039989A1 (en) * 2018-03-01 2020-02-06 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of dyrk/clk and uses thereof
WO2019186277A1 (en) 2018-03-28 2019-10-03 Institut Pasteur Ultrasensitive hiv-1 p24 detection assay
EP3594205A1 (en) * 2018-07-09 2020-01-15 Abivax Phenyl-n-aryl derivatives for treating a rna virus infection
WO2020128033A1 (en) 2018-12-20 2020-06-25 Institut Pasteur Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells
EP3669874A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use in the treatment or prevention of cancer
EP3669873A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases
JP2022532258A (ja) 2019-05-15 2022-07-13 アロンバイオ リミテッド 癌の治療、ケモカイン活性の阻害および／または細胞死の誘導のための小分子
CN115279345A (zh) * 2020-01-31 2022-11-01 Abivax公司 8-氯-n-(4-(三氟甲氧基)苯基)喹啉-2-胺的无定形固体分散体
EP3858336A1 (en) 2020-01-31 2021-08-04 Abivax Amorphous solid dispersion of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine
EP3858815A1 (en) 2020-01-31 2021-08-04 Abivax Co-crystals and salts of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine
WO2021186053A1 (en) 2020-03-20 2021-09-23 Abivax Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
EP4175719A1 (en) 2020-07-02 2023-05-10 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
EP4063351A1 (en) 2021-03-26 2022-09-28 Abivax Preparation method of quinoline derivative compounds
WO2022247920A1 (zh) 2021-05-27 2022-12-01 江苏恒瑞医药股份有限公司 喹啉胺类化合物、其制备方法及其在医药上的应用
KR20230072900A (ko) 2021-11-18 2023-05-25 동우 화인켐 주식회사 마이크로 led 구조체 및 이의 제조방법
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator
EP4215196A1 (en) 2022-01-24 2023-07-26 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor
TW202333698A (zh) * 2022-01-24 2023-09-01 大陸商江蘇恆瑞醫藥股份有限公司 喹啉胺類化合物、其製備方法及其在醫藥上的應用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR400973A (fr) 1909-03-19 1909-08-13 Jean Victor Massillon Nouveau sertisseur à main pour la fabrication des cartouches
GB585362A (en) 1944-08-31 1947-02-05 Francis Henry Swinden Curd New heterocyclic compounds
BE486034A (ja) 1947-11-28
DE958647C (de) 1952-12-28 1957-02-21 Hoechst Ag Verfahren zur Herstellung von 7-Amino-2-oxy-4-methyl-chinolinen
FR2387229A1 (fr) 1977-04-13 1978-11-10 Anvar Dipyrido (4,3-b) (3,4-f) indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant
FR2436786A1 (fr) 1978-09-21 1980-04-18 Anvar Nouveaux derives des pyrido (4,3-b) carbazoles (ellipticines), substitues en position 1 par une chaine polyaminee, leur obtention et leur application a titre de medicaments
FR2627493B1 (fr) * 1988-02-23 1991-10-31 Sanofi Sa Procede de preparation de derives d'isoquinoleine
FR2645861A1 (fr) 1989-04-17 1990-10-19 Inst Nat Sante Rech Med Utilisation de dipyrido (4,3-b) (3,4-f) indoles pour la preparation de medicaments utiles pour le traitement du sida
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
WO2000059875A2 (en) 1999-04-05 2000-10-12 City Of Hope Novel inhibitors of formation of advanced glycation endproducts (age's)
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
DE10013318A1 (de) * 2000-03-17 2001-09-20 Merck Patent Gmbh Formulierung enthaltend Chinoxalinderivate
AU2002303078B2 (en) 2001-01-22 2007-08-30 Memory Pharmaceuticals Corporation Aniline derivatives useful as phosphodiesterase 4 inhibitors
ES2355472T3 (es) 2002-05-22 2011-03-28 Amgen Inc. Derivados de aminopirimidina para su uso como ligandos del receptor vaniloide para el tratamiento del dolor.
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
BR0312999A (pt) * 2002-07-19 2005-06-07 Memory Pharm Corp Compostos, composições farmacêticas, método para aumentar a cognição, de tratamento, de inibição da atividade de enzima pde4 em um paciente
WO2006081444A2 (en) 2005-01-28 2006-08-03 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
FR2849474B3 (fr) 2002-12-27 2004-12-03 Olivier Jean Noel Juin Installation de transformation de l'energie cinetique d'un fluide en energie electrique
WO2004078731A1 (fr) 2003-03-06 2004-09-16 'chemical Diversity Research Institute', Ltd. Acides quinoline-carboxyliques et leurs derives et bibliotheque focalisee
CA2518398A1 (en) * 2003-03-10 2004-09-23 Schering Corporation Heterocyclic kinase inhibitors: methods of use and synthesis
FR2859475A1 (fr) 2003-09-04 2005-03-11 Centre Nat Rech Scient Utilisation de composes derives d'ellipticine et d'aza-ellipticine pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage
FR2859474B1 (fr) 2003-09-04 2006-01-13 Centre Nat Rech Scient Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage
CN1882345A (zh) * 2003-10-16 2006-12-20 希龙公司 作为raf激酶抑制剂以治疗癌症的2,6－二取代的喹唑啉、喹喔啉、喹啉和异喹啉
EP1689387B1 (en) * 2003-11-19 2011-09-14 Array Biopharma, Inc. Bicyclic inhibitors of mek and methods of synthesis thereof
CA2585490A1 (en) * 2004-11-12 2006-05-18 Galapagos Nv Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
CN101213260A (zh) * 2005-06-29 2008-07-02 株式会社Adeka 树脂添加剂组合物和其树脂组合物
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
WO2008008234A1 (en) * 2006-07-07 2008-01-17 Targegen, Inc. 2-amino-5-substituted pyrimidine inhibitors
AU2008206045A1 (en) * 2007-01-19 2008-07-24 Ardea Biosciences, Inc. Inhibitors of MEK
FR2912745A1 (fr) 2007-02-19 2008-08-22 Centre Nat Rech Scient Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant
US20100249184A1 (en) * 2007-03-16 2010-09-30 Mount Sinai School Of Medicine Induction and/or maintenance of tumor dormancy by disruption of urokinase plasminogen activator receptor-integrin interaction
JP5603233B2 (ja) * 2007-05-17 2014-10-08 エルジー・ケム・リミテッド 新規なアントラセン誘導体およびそれを用いた有機電子素子
UY31272A1 (es) * 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
MX2010001576A (es) 2007-08-15 2010-09-14 Memory Pharm Corp Compuestos 3´sustituidos que tienen afinidad con el receptor 5-hidroxitriptamina 6 (5-ht6).
WO2009029617A1 (en) * 2007-08-27 2009-03-05 Kalypsys, Inc. Diarylamine-substituted quinolones useful as inducible nitric oxide synthase inhibitors
KR100974562B1 (ko) * 2007-12-31 2010-08-06 다우어드밴스드디스플레이머티리얼 유한회사 신규한 유기 발광 화합물 및 이를 발광재료로서 채용하고있는 유기 발광 소자
FR2926297B1 (fr) 2008-01-10 2013-03-08 Centre Nat Rech Scient Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage.
EP2384337A1 (en) * 2009-01-05 2011-11-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Means and method for the treatment of antibody deficiency diseases based on il-21 and il-21 variants
US20120172617A1 (en) * 2009-01-06 2012-07-05 Werner Bonrath resveratrol intermediates dal
ES2630226T3 (es) * 2009-01-06 2017-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Un agente agotador de células B para el tratamiento de la aterosclerosis
CN106928194B (zh) 2009-06-12 2019-11-12 Abivax公司 用于治疗过早衰老和尤其是早衰的化合物
MX2019008390A (es) * 2009-06-12 2019-09-09 Abivax Compuestos utiles para tratar cancer.
EP2266972A1 (en) 2009-06-12 2010-12-29 Splicos New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies
US8962583B2 (en) 2009-06-25 2015-02-24 The Brigham And Women's Hospital, Inc. Treatment of inflammatory diseases using miR-124
EP2465502A1 (en) 2010-12-15 2012-06-20 Société Splicos Compounds useful for treating AIDS
JP2016504268A (ja) 2012-10-04 2016-02-12 オヤジェン インコーポレイテッドＯｙａＧｅｎ， Ｉｎｃ． Ｖｉｆの自己会合を撹乱する抗ｈｉｖ剤としての小分子及びその使用方法
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
JP2015120566A (ja) * 2013-12-20 2015-07-02 ニチユ三菱フォークリフト株式会社 荷役車両

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11441181B2 (en) 2013-01-17 2022-09-13 Abivax miRNA-124 as a biomarker
US11649211B2 (en) 2014-07-17 2023-05-16 Abivax Use of quinoline derivatives for the treatment of inflammatory diseases
US11649210B2 (en) 2014-07-17 2023-05-16 Abivax Use of quinoline derivatives for the treatment of inflammatory diseases
US10464903B2 (en) * 2016-03-18 2019-11-05 Ratiopharm Gmbh Process for preparing quinolin-2-yl-phenylamine derivatives and their salts
US10745357B2 (en) * 2016-03-18 2020-08-18 Ratiopharm Gmbh Process for preparing quinolin-2-yl-phenylamine derivatives and their salts
US11992499B2 (en) 2018-12-20 2024-05-28 Abivax Quinoline derivatives for use in the treatment of inflammation diseases

Also Published As

Publication number Publication date
BRPI1010772B8 (pt) 2021-05-25
HK1173447A1 (zh) 2013-05-16
BRPI1010768A8 (pt) 2019-07-30
BRPI1010768B8 (pt) 2020-03-10
KR20180100735A (ko) 2018-09-11
CN106905232A (zh) 2017-06-30
CN104945379B (zh) 2018-11-30
CN104844510A (zh) 2015-08-19
BR122019013686B1 (pt) 2020-03-17
AU2010258214A1 (en) 2012-01-19
CA2764027A1 (en) 2010-12-16
HUE061262T2 (hu) 2023-05-28
BRPI1012892B1 (pt) 2020-10-27
CA2764026A1 (en) 2010-12-16
HK1200363A1 (en) 2015-08-07
CU20110229A7 (es) 2012-06-21
US20140288120A1 (en) 2014-09-25
CN106905232B (zh) 2019-09-27
PL2440546T3 (pl) 2023-07-10
KR20170124646A (ko) 2017-11-10
US10017498B2 (en) 2018-07-10
US20120283265A1 (en) 2012-11-08
CN102596935B (zh) 2015-02-18
ES2938532T3 (es) 2023-04-12
KR101982461B1 (ko) 2019-05-24
KR102016893B1 (ko) 2019-08-30
EP2440547B1 (en) 2022-11-30
HK1212702A1 (zh) 2016-06-17
KR101982463B1 (ko) 2019-05-24
CN104945379A (zh) 2015-09-30
PT2440546T (pt) 2023-03-27
CN106928205B (zh) 2019-09-24
JP2012529494A (ja) 2012-11-22
CU24461B1 (es) 2020-01-03
WO2010143170A2 (en) 2010-12-16
KR102016891B1 (ko) 2019-08-30
EP2440546B1 (en) 2022-12-28
BRPI1010772B1 (pt) 2020-10-27
CA2764026C (en) 2019-10-29
JP2015155453A (ja) 2015-08-27
HK1173726A1 (zh) 2013-05-24
TR201910781T4 (tr) 2019-08-21
CA2764027C (en) 2020-11-03
ES2736198T3 (es) 2019-12-26
US20150299129A1 (en) 2015-10-22
MX364279B (es) 2019-04-22
KR101863021B1 (ko) 2018-05-30
US9637475B2 (en) 2017-05-02
MX364280B (es) 2019-04-22
HUE045548T2 (hu) 2019-12-30
KR20180101727A (ko) 2018-09-13
KR102016890B1 (ko) 2019-08-30
KR102016889B1 (ko) 2019-08-30
MX2011013122A (es) 2012-07-23
ZA201109032B (en) 2013-02-27
EP2440546A2 (en) 2012-04-18
RU2567752C2 (ru) 2015-11-10
US9908869B2 (en) 2018-03-06
KR20180100737A (ko) 2018-09-11
MX364282B (es) 2019-04-22
CU24245B1 (es) 2017-02-02
CN106928194B (zh) 2019-11-12
AU2010258294B2 (en) 2015-07-30
BRPI1010768C8 (pt) 2020-04-07
MX340095B (es) 2016-06-27
MX364989B (es) 2019-05-17
MX353776B (es) 2018-01-29
AU2010258214B2 (en) 2015-08-20
CN103948594B (zh) 2016-10-26
WO2010143168A2 (en) 2010-12-16
KR101973348B1 (ko) 2019-04-26
CU24093B1 (es) 2015-04-29
JP7042245B2 (ja) 2022-03-25
CN104844510B (zh) 2019-04-23
CN109776496B (zh) 2021-09-28
JP2020045342A (ja) 2020-03-26
FI2440547T3 (fi) 2023-03-14
CN104844570A (zh) 2015-08-19
US20120329796A1 (en) 2012-12-27
RU2011149571A (ru) 2013-07-20
EP4198022A1 (en) 2023-06-21
BRPI1010768B1 (pt) 2019-10-22
MX367601B (es) 2019-08-28
KR101789275B1 (ko) 2017-11-20
FI2440546T3 (fi) 2023-03-30
KR20190018570A (ko) 2019-02-22
JP6041671B2 (ja) 2016-12-14
KR20190018569A (ko) 2019-02-22
WO2010143170A3 (en) 2011-08-11
WO2010143169A3 (en) 2011-11-10
JP5826745B2 (ja) 2015-12-02
HRP20230248T1 (hr) 2023-04-14
JP6158250B2 (ja) 2017-07-05
CN109776496A (zh) 2019-05-21
JP2015187152A (ja) 2015-10-29
EP3517534B1 (en) 2024-02-28
HK1173153A1 (en) 2013-05-10
AU2010258295B2 (en) 2015-09-03
CU20110230A7 (es) 2012-04-15
US20140080831A1 (en) 2014-03-20
LT2440547T (lt) 2023-03-10
BRPI1010772A2 (pt) 2016-11-01
SI2440547T1 (sl) 2023-05-31
BRPI1012892B8 (pt) 2021-05-25
CN104945378B (zh) 2018-11-20
HK1212990A1 (zh) 2016-06-24
HK1213246A1 (zh) 2016-06-30
CU20110228A7 (es) 2012-04-15
CU24124B1 (es) 2015-08-27
JP2012529495A (ja) 2012-11-22
KR102016892B1 (ko) 2019-08-30
CN106928205A (zh) 2017-07-07
EP2440547A2 (en) 2012-04-18
FI3517534T3 (fi) 2024-05-16
AU2010258294A1 (en) 2012-01-19
JP2015187151A (ja) 2015-10-29
CA2965791C (en) 2020-06-09
KR20190018567A (ko) 2019-02-22
HK1213247A1 (zh) 2016-06-30
JP6158251B2 (ja) 2017-07-05
JP5905385B2 (ja) 2016-04-20
RU2011149572A (ru) 2013-07-20
CU20150024A7 (es) 2015-09-29
WO2010143169A2 (en) 2010-12-16
BR122019013687B1 (pt) 2020-04-14
KR101769616B1 (ko) 2017-08-18
KR20190018568A (ko) 2019-02-22
BRPI1010768A2 (pt) 2016-11-01
DK2440547T3 (da) 2023-02-20
CN106928194A (zh) 2017-07-07
CN102574835A (zh) 2012-07-11
CA3070823C (en) 2021-09-21
KR20180100736A (ko) 2018-09-11
CN113004249A (zh) 2021-06-22
EP3517534A1 (en) 2019-07-31
WO2010143168A3 (en) 2011-06-09
KR20120049860A (ko) 2012-05-17
CA2764024A1 (en) 2010-12-16
EP3521283A1 (en) 2019-08-07
CA2764024C (en) 2017-12-05
MX2011013119A (es) 2012-07-04
ES2940885T3 (es) 2023-05-12
KR101982462B1 (ko) 2019-05-24
PL2440547T3 (pl) 2023-09-11
CN102574835B (zh) 2014-04-16
BRPI1012892A2 (pt) 2018-03-13
PT2440545T (pt) 2019-07-19
KR20120054585A (ko) 2012-05-30
CN102625804A (zh) 2012-08-01
HRP20230143T1 (hr) 2023-03-31
US9108919B2 (en) 2015-08-18
CN104945378A (zh) 2015-09-30
KR20120051643A (ko) 2012-05-22
CN102625804B (zh) 2015-04-08
PL2440545T3 (pl) 2019-11-29
AU2010258295A1 (en) 2012-01-19
MX359575B (es) 2018-10-03
MX338823B (es) 2016-05-03
KR101897221B1 (ko) 2018-09-10
EP2440545A2 (en) 2012-04-18
CN103948594A (zh) 2014-07-30
CN104844570B (zh) 2018-11-02
CN102596935A (zh) 2012-07-18
US9145367B2 (en) 2015-09-29
DK2440546T3 (da) 2023-03-27
KR20190018571A (ko) 2019-02-22
US20150307478A1 (en) 2015-10-29
PT2440547T (pt) 2023-02-17
MX2011013120A (es) 2012-07-23
EP2440545B1 (en) 2019-04-24
DK2440545T3 (da) 2019-07-22
JP2015187150A (ja) 2015-10-29
EP3521283B1 (en) 2024-02-28
CA3070823A1 (en) 2010-12-16
JP2012529493A (ja) 2012-11-22
CA2965791A1 (en) 2010-12-16
KR20170092720A (ko) 2017-08-11
ZA201109031B (en) 2013-02-27

Similar Documents

Publication Publication Date Title
US9637475B2 (en) Compounds for treating cancer
US10975063B2 (en) Compound, and production method thereof, and methods of treatment using the compound
JP6336650B2 (ja) ガンを治療する為に有用な化合物
AU2019203896B2 (en) Compounds useful for treating cancer
US20220127253A1 (en) Compounds for preventing, inhibiting, or treating cancer, aids and/or premature aging

Legal Events

Date Code Title Description
AS Assignment

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, FRAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ROUX, PIERRE;MAHUTEAU, FLORENCE;NAJMAN, ROMAIN;AND OTHERS;SIGNING DATES FROM 20120113 TO 20120120;REEL/FRAME:028553/0630

Owner name: INSTITUT CURIE, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ROUX, PIERRE;MAHUTEAU, FLORENCE;NAJMAN, ROMAIN;AND OTHERS;SIGNING DATES FROM 20120113 TO 20120120;REEL/FRAME:028553/0630

Owner name: UNIVERSITE MONTPELLIER 2, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ROUX, PIERRE;MAHUTEAU, FLORENCE;NAJMAN, ROMAIN;AND OTHERS;SIGNING DATES FROM 20120113 TO 20120120;REEL/FRAME:028553/0630

Owner name: SOCIETE SPLICOS CAMPUS DU CNRS, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ROUX, PIERRE;MAHUTEAU, FLORENCE;NAJMAN, ROMAIN;AND OTHERS;SIGNING DATES FROM 20120113 TO 20120120;REEL/FRAME:028553/0630

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION